comprehensive -WSS

comprehensive

author：explore 2025-10-01 15:28:15 - browse：575

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： STAT letters to the editor on burnt

focus

WSS

Leukemia patients are helped by Syndax's new type of therapy

Congenital heart disease patients face new threat of heart failure

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Americans' trust in science, scientist continues decline: Report

Roche to buy Carmot Therapeutics, developer of obesity drugs

STAT letters to the editor on burnt

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

hotspot

Supreme Court strikes down use of affirmative action

Why sickle cell disease is getting the first CRISPR treatment

Psychedelics group wrestles with new pharma identity

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Cancer drug shortages should be causing more outrage

Lawmakers grill UnitedHealth CEO on Change cyberattack

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What PEPFAR has meant on the ground in Ukraine

Tori Bowie and the unacceptable rates of Black maternal death

Deliver public health messages at the right time

leisure time

What PEPFAR has meant on the ground in Ukraine

Sepsis can kill a child within hours. Here's how hospitals are fighting back

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Why sickle cell disease is getting the first CRISPR treatment

Has Bernie Sanders reached the limit of his pharma bullying effort?

Empower primary care with adequate payments and technology

entertainment

focus

entertainment

leisure time